Drugs / AFM28
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05817058 | Mar 2023 → Nov 2024 | acute myeloid leukemia | Affimed GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFM28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05817058 ↗ |
| Modality | Monoclonal antibody | “AFM28 is a tetravalent monoclonal antibody” NCT05817058 ↗ |